Overview

A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors

Status:
Completed
Trial end date:
2018-01-20
Target enrollment:
Participant gender:
Summary
This is a study in patients with advanced solid tumors for the investigation of P-gp inhibition and induction on the PK of talazoparib.
Phase:
Phase 1
Details
Lead Sponsor:
Medivation, Inc.
Pfizer
Collaborator:
Medivation, Inc.
Treatments:
Hydroxyitraconazole
Itraconazole
Rifampin
Talazoparib